NEUROGENE INC.
- Country
- πΊπΈUnited States
- Ownership
- Private, Subsidiary
- Established
- 2003-12-01
- Employees
- 56
- Market Cap
- -
- Website
- https://www.neoleukin.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)β’ Click on a phase to view related trials
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
- Conditions
- Rett Syndrome
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Neurogene Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT05898620
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUCSF Benioff Children's Hospital Oakland, Oakland, California, United States
πΊπΈNicklaus Children's Hospital Research Institute, Miami, Florida, United States
Gene Therapy Study for Children With CLN5 Batten Disease
- Conditions
- Neuronal Ceroid Lipofuscinosis CLN5
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Neurogene Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05228145
- Locations
- πΊπΈ
University of Rochester, Rochester, New York, United States
π¬π§Great Ormond Street Hospital for Children, London, United Kingdom
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
- Conditions
- Advanced Solid TumorSolid Tumor
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Neurogene Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT04659629
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈProvidence Cancer Center Oncology and Hematology Care Clinic, Portland, Oregon, United States
πΊπΈUT- MD Anderson, Houston, Texas, United States
A Natural History Study of Aspartylglucosaminuria
- Conditions
- AspartylglucosaminuriaAspartylglucosamidase (AGA) DeficiencyLysosomal Storage Diseases
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Neurogene Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03853876
- Locations
- πΊπΈ
University of Texas Southwestern, Dallas, Texas, United States
A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)
- Conditions
- Ceroid Lipofuscinosis, Neuronal 5
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Neurogene Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03822650
- Locations
- πΊπΈ
University of Rochester Medical Center, Rochester, New York, United States
- Prev
- 1
- 2
- Next